Forfivo Xl is owned by Almatica.
Forfivo Xl contains Bupropion Hydrochloride.
Forfivo Xl has a total of 1 drug patent out of which 0 drug patents have expired.
Forfivo Xl was authorised for market use on 10 November, 2011.
Forfivo Xl is available in tablet, extended release;oral dosage forms.
The generics of Forfivo Xl are possible to be released after 25 June, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7674479||ALMATICA||Sustained-release bupropion and bupropion/mecamylamine tablets|| |
(4 years from now)
Market Authorisation Date: 10 November, 2011
Dosage: TABLET, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic